Client: Photo Therapeutics
Project: Omnilux Phototherapy Skin Cancer Treatment Device
Expertise: Medical Device Development
Putting people first helps develop products with longevity
- Innovative medical device development
- Significant cost saving over surgery
- Nine months to design and develop
- Anthropometric research and user observation
- Industrial design and mechanism development
- Prototypes assembled and tested by Lucid
- International supplier sourcing
- Standards-compliant design information
Skin cancer rates are growing, with non-melanoma cancers most common. Clinical trials of photo-dynamic therapies at Cancer Research UK’s Patterson Institute offered the prospect of a non-surgical option, improving both patient experiences and treatment outcomes.
Photo Therapeutics Ltd was spun out to commercialise research that indicated a skin-applied photo-sensitising drug, under controlled light could drive some cancers into remission.
The Omnilux product offer is based around a single nurse delivering effective therapies, freeing up surgical teams and theatres and significantly reducing treatment cost.
Discovering a way to make the treatment work for users – i.e. real patients in real clinics – really was starting from first principles. Nothing directly comparable existed.
Our medical device designers immersed themselves in the patient and clinician experience. We observed clinical trials and created basic models to role-play alternative design options.
We measured treatment environments and surveyed users on how comparable devices were stored and maintained, considering all the stakeholders involved.
We used anthropometric data to optimise the light array design to fit patients’ varied physiques. Thermal and mechanical development was accelerated by extensive CAD analysis and rapid prototyping.
Lucid’s ability to think about big-picture without losing focus on the nuts-and-bolts of how a device could work is a real asset to our business.
– Philip Charlton: Financial Director, Photo Therapeutics
Omnilux has delivered a decade of sales for Photo Therapeutics, a research spin-out that became a multi-million dollar business, eventually acquired by US-based Photomedex Inc.